RxDoctor Payments Data

Jerry Rittenhouse, MD

Urology · Stoneham, MANPI 1831124916

Payments from drug & device makers

$1,884in general payments, 2019–2025

Across 30 payments — averaging $62.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$1K
  • Astellas Pharma US Inc$327
  • Pfizer$162
  • Axonics, Inc.$102
  • AbbVie$91
  • Boston Scientific$56
  • plus $13 from 1 others

What the payments were for

  • Travel & lodging$1,03855%
  • Food & beverage$71338%
  • Education$1327%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Coloplast4$1,132
Astellas Pharma US Inc7$327
Pfizer10$162
Axonics, Inc.2$102
AbbVie(2 entities)5$91
Boston Scientific1$56
Urovant Sciences Inc1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,884 in reported general payments places this provider in the 50th percentile of 327 urology providers in Massachusetts.

See all urology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$29,286
Medicare patients
188
Services billed
350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron227$171,805
GemtesaVibegron14$19,403
Mirabegron ErMirabegron15$10,733
Tamsulosin Hcl622$9,822
Methenamine Hippurate66$6,720
Estradiol85$5,682
Finasteride339$4,977
Fesoterodine Fumarate ErFesoterodine Fumarate25$3,693
Trospium Chloride61$2,902
Testosterone23$2,599
Dutasteride68$2,471
Silodosin32$2,315
Potassium Citrate ErPotassium Citrate16$1,658
Cephalexin207$1,302
Testosterone Cypionate58$942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$327$171,805227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 327 urology providers in Massachusetts.

Other urology in Stoneham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →